Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AIMEE L PIERCE

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1043484801
CMS profile
535451
Location
PORTLAND, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,461.27

17 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,079.95 7
Food and Beverage $229.32 6
Education $152.00 4

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Eisai Inc. $1,309.27 13
Genentech, Inc. $152.00 4

Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AIMEE L PIERCE

NPI 1043484801 · CMS profile ID 535451

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

PORTLAND, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043484801?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AIMEE L PIERCE, NPI 1043484801, CMS profile ID 535451. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043484801?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). AIMEE L PIERCE, NPI 1043484801, CMS profile ID 535451. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043484801?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
AIMEE L PIERCE, NPI 1043484801, CMS profile ID 535451, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1043484801?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

17 matching records · $1,461.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 17 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–17 of 17.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eisai Inc. $27.8408/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698079959 CMS
Eisai Inc. $186.6708/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698079961 CMS
Eisai Inc. $536.0208/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698079963 CMS
Eisai Inc. $131.7508/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698079965 CMS
Eisai Inc. $83.6708/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698079967 CMS
Eisai Inc. $79.3908/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698079969 CMS
Eisai Inc. $54.0008/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698079971 CMS
Eisai Inc. $60.0008/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698079973 CMS
Eisai Inc. $50.0008/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698079975 CMS
Eisai Inc. $12.4808/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698079977 CMS
Eisai Inc. $49.9808/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698079979 CMS
Eisai Inc. $12.4808/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698079981 CMS
Eisai Inc. $24.9908/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698079983 CMS
Genentech, Inc. $38.0001/14/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681163532 CMS
Genentech, Inc. $38.0001/14/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681166177 CMS
Genentech, Inc. $38.0001/14/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681168175 CMS
Genentech, Inc. $38.0001/14/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681174845 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,461.27 17
PY2025 $145.64 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $566,660.00 28
PY2024 Principal investigator $160,708.92 10
PY2023 Principal investigator $364,639.80 34
PY2022 Recipient $540.00 1
PY2022 Principal investigator $574,355.63 59
PY2021 Principal investigator $357,643.14 51
PY2020 Recipient $54.30 1
PY2020 Principal investigator $441,392.01 66
PY2019 Principal investigator $521,940.15 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

34 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eisai Inc. $1,800.90 12/19/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025442155
Principal investigator 1 Eisai Inc. $22,065.00 12/14/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1039935125
Principal investigator 1 Eisai Inc. $9,570.00 12/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442149
Principal investigator 1 Eisai Inc. $19,345.00 12/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442151
Principal investigator 1 Eisai Inc. $1,515.00 12/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442153
Principal investigator 1 Eisai Inc. $7,584.60 11/13/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025442157
Principal investigator 1 Eisai Inc. $19,425.00 10/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442137
Principal investigator 1 Eisai Inc. $17,985.00 10/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442139
Principal investigator 1 Eisai Inc. $1,290.00 10/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442141
Principal investigator 1 Eisai Inc. $25,220.00 10/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442143
Principal investigator 1 Eisai Inc. $20,505.00 10/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442145
Principal investigator 1 Eisai Inc. $3,840.00 10/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442147
Principal investigator 1 Eisai Inc. $1,510.00 09/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442131
Principal investigator 1 Eisai Inc. $15,350.00 09/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442133
Principal investigator 1 Eisai Inc. $16,045.00 09/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442135
Principal investigator 1 Eisai Inc. $14,527.80 08/07/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025442105
Principal investigator 1 Eisai Inc. $15,220.00 08/07/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025442107
Principal investigator 1 Eisai Inc. $25,605.00 06/30/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442125
Principal investigator 1 Eisai Inc. $23,629.00 06/30/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442127
Principal investigator 1 Eisai Inc. $7,675.00 06/30/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442129
Principal investigator 1 Eli Lilly and Company $412.50 04/25/2023 Non-covered Recipient Entity
SEATTLE INSTITUTE FOR BIOMED AND CLINICAL RSRCH
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY No dispute reported 06/30/2026 1038144131
Principal investigator 1 Eisai Inc. $1,510.00 04/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442119
Principal investigator 1 Eisai Inc. $8,795.00 04/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442121
Principal investigator 1 Eisai Inc. $1,290.00 04/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442123
Principal investigator 1 Eisai Inc. $11,040.00 03/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442117
Principal investigator 1 ABBVIE INC. $850.00 02/08/2023 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimers Disease No dispute reported 06/30/2026 998359859
Principal investigator 1 Eli Lilly and Company $12,975.00 02/08/2023 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY No dispute reported 06/30/2026 1038062237
Principal investigator 1 Eisai Inc. $6,500.00 02/07/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025442103
Principal investigator 1 ABBVIE INC. $550.00 02/02/2023 Covered Recipient Teaching Hospital
OHSU HOSPITAL AND CLINICS
An Extension Study of ABBV-8E12 in Early Alzheimers Disease (AD) No dispute reported 06/30/2026 998359855
Principal investigator 1 Eisai Inc. $29,640.00 02/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442111
Principal investigator 1 Eisai Inc. $13,195.00 02/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442113
Principal investigator 1 Eisai Inc. $5,075.00 02/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442115
Principal investigator 1 Eli Lilly and Company $550.00 01/31/2023 Non-covered Recipient Entity
FEINSTEIN INSTITUTE FOR MEDICAL
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY No dispute reported 06/30/2026 1038090931
Principal investigator 1 Eisai Inc. $2,550.00 01/01/2023 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1025442109